High low-density lipoprotein cholesterol levels in people with HIV by individual cardiovascular risk: A retrospective observational study

People with HIV (PWH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). Lowering low-density lipoprotein cholesterol (LDL-C) is central of cardiovascular disease prevention. The aim of this study was to assess the prevalence, treatment, and control of high LDL-C levels as asse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2025-02, Vol.420, p.132742, Article 132742
Hauptverfasser: Carrozzo, Giorgia, Caloni, Beatrice, Giacomelli, Andrea, Oreni, Letizia, Caronni, Stefania, Lazzarin, Samuel, Poloni, Andrea, Pagano, Simone, Colombo, Martina Laura, Beltrami, Martina, Casalini, Giacomo, Maggioni, Aldo Pietro, Gervasoni, Cristina, Ridolfo, Anna Lisa, Antinori, Spinello
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:People with HIV (PWH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). Lowering low-density lipoprotein cholesterol (LDL-C) is central of cardiovascular disease prevention. The aim of this study was to assess the prevalence, treatment, and control of high LDL-C levels as assessed on the basis of the ASCVD risk profiles indicated by European Society of Cardiology (ESC) guidelines of a cohort of PWH in order to evaluate the state of LDL-C management in current clinical practice. We retrospectively assessed the prevalence, treatment, and control of high LDL-C levels in a cohort of PWH aged ≥40 years who accessed our HIV outpatient clinic between 1 March 2022 and 31 March 2023. Their 10-year ASCVD risk was calculated on the basis of their age and co-morbidities as recommended by guidelines. High LDL-C levels were defined as those above the “step two” target of their specific ASCVD risk category. Among the 1404 assessed PWH, who were prevalently male (74.5 %) and Caucasian (85.6 %), and had a median age of 56 years (interquartile range [IQR] 49–61), 295 (21 %) were at very high risk (VHR), 634 (45.2 %) at high-risk (HR), and 348 (24.8 %) not at HR. The overall median LDL-C level was 116 mg/dL (IQR 96–141). Five hundred and sixteen (37 %) were undergoing lipid lowering treatment (LLT), and 650 (46.3 %) failed to achieve any step of their target LDL-C levels. Despite the high prevalence of PWH at VHR/HR for ASCVD, LDL-C levels were poorly controlled and LLT was greatly under used. [Display omitted] •People with HIV are at increased risk of atherosclerotic cardiovascular disease.•Lowering low-density lipoprotein cholesterol is central for prevention.•2021 ESC guidelines identified target for LDL-C applied in 2023 EACS guidelines.•A high proportion of PWH failed to achieve any step of their target LDL-C levels.•A large underutilization of lipid lowering treatments was observed in PWH.
ISSN:0167-5273
1874-1754
1874-1754
DOI:10.1016/j.ijcard.2024.132742